Foundation Medicine, Inc.
FMI
FMI was delisted on the 30th of July, 2018.
0 hedge funds and large institutions have $0 invested in Foundation Medicine, Inc. in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 156 closing their positions.
100% less funds holding
Funds holding: 157 → 0 (-157)
100% less funds holding in top 10
Funds holding in top 10: 7 → 0 (-7)
100% less capital invested
Capital invested by funds: $1.86B → $0 (-$1.86B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 156
Top Buyers
Top Sellers
| 1 |
BlackRock
New York
|
-$200M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$183M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$175M |
| 4 |
State Street
Boston,
Massachusetts
|
-$119M |
| 5 |
Chevy Chase Trust
Bethesda,
Maryland
|
-$111M |
FMI Hedge Fund Activity: Q3 2018 in Review
0 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Foundation Medicine, Inc. (FMI) for Q3 2018, worth a combined $0 — down 100% from $1.86B a quarter earlier.
Sellers outnumbered buyers: 156 funds closed out of FMI and 0 opened new positions — a net loss of 156 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $200M sold.
- 0 institutional investors held Foundation Medicine, Inc. (FMI) as of Q3 2018, down from 157 in Q2 2018.
- Funds reported $0 of Foundation Medicine, Inc. stock for Q3 2018, down 100% quarter-over-quarter.
- 0 funds opened new Foundation Medicine, Inc. positions in Q3 2018 and 156 closed out, a net change of -156 holders.
- The largest Foundation Medicine, Inc. seller in Q3 2018 was BlackRock, an estimated $200M sold.
Based on aggregated 13F filings for Q3 2018.